INS and type 2 diabetes mellitus: Using the STZ-induced diabetic rat model, researchers found that a main PPT-type ginsenoside, Rg1, can lower insulin resistance and blood glucose, and also improve the blood lipid profile and liver function [32], suggesting that Rg1 may be a potential adjuvant therapy for type 2 diabetic patients with fatty liver disease.